On September 30, 2021, Exicure, Inc. ("Exicure") and Exicure Operating Company, Exicure’s wholly owned subsidiary (collectively with Exicure, the "Company") reported that entered into an amendment ("Amendment No. 3") to the Company’s Credit and Security Agreement, dated as of September 25, 2020, as amended on October 21, 2020 and July 30, 2021, with MidCap Financial Trust, as agent, and the lenders party thereto from time to time (as amended by Amendment No. 3, the "Credit Agreement") (Filing, 8-K, Exicure, SEP 30, 2021, View Source [SID1234590895]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Amendment No. 3 extends the availability of the second advance of $7.5 million under the Credit Agreement from September 30, 2021 to December 31, 2021, subject to the Company’s satisfaction of certain applicable funding conditions as described in Amendment No. 3, including i.) Exicure’s issuance of equity interests, subject to certain limitations, resulting in receipt by Exicure of unrestricted net cash proceeds of at least $20.0 million, and ii.) the contribution by Exicure, and receipt by Exicure Operating Company, of such cash proceeds to the capital of Exicure Operating Company.